Use of metformin in obese adolescents with hyperinsulinemia: A 6-month, randomized, double-blind, placebo-controlled clinical trial

Basit Öğe Kaydı
dc.contributor.authorAtabek, Mehmet Emre
dc.contributor.authorPirgon, Ozgur
dc.date.accessioned2020-03-26T17:28:24Z
dc.date.available2020-03-26T17:28:24Z
dc.date.issued2008
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractAim: To determine whether metformin treatment for 6 months is effective in reducing body weight and hyperinsulinemia and also ameliorating insulin sensitivity indices in obese adolescents with hyperinsulinemia. Methods: One hundred and twenty adolescents (age range 9-17 years) with BMI > 95(th) percentile for age and sex were included (metformin group, n 90 [45 females, 45 males]; placebo group, n 30 [15 females, 15 males]). The groups received 500 mg metformin (n = 90) or placebo (n = 30) twice daily for 6 months, plus individually tailored diet, exercise and behavioral therapy. Hyperinsulinism and insulin sensitivity indices were defined from fasting samples. Oral glucose tolerance tests were performed before and after treatment. Results: Before treatment, there were no significant differences between the metformin group and control group in terms of anthropometric data and metabolic parameters. After metformin, there was a significant decline in body mass index (from 28.5 +/- 3.4 to 26.7 +/- 4 kg/m(2), p < 0.001), fasting insulin (from 19.2 +/- 10.4 to 11.1 +/- 6.1 mu U/ml, p < 0.001) and 120 min insulin levels (from 103.7 +/- 73.8 to 49.8 +/- 30.9 mu U/ml, p < 0.001). FGIR increased significantly from 6.26 +/- 3.0 to 12.5 +/- 10.6 (p < 0.001) and HOMA-IR was reduced from 4.95 +/- 3.34 to 2.6 +/- 1.6 (p < 0.001) after treatment. QUICKI significantly increased from 0.31 +/- 0.02 to 0.34 +/- 0.03 (p < 0.001) in the metformin group. Moreover, in comparison of changes in insulin sensitivity indices between the metformin treated and control groups, the metformin treated. group showed significantly improved metabolic control at the end of the study. Conclusion: These data suggest that metformin treatment is effective in reducing insulin resistance and also ameliorating metabolic complications of insulin resistance syndrome in obese adolescents with hyperinsulinemia.en_US
dc.identifier.endpage348en_US
dc.identifier.issn0334-018Xen_US
dc.identifier.issue4en_US
dc.identifier.pmid18556965en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage339en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12395/22774
dc.identifier.volume21en_US
dc.identifier.wosWOS:000256605700007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherFREUND PUBLISHING HOUSE LTDen_US
dc.relation.ispartofJOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISMen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectmetforminen_US
dc.subjectchildhood obesityen_US
dc.subjectinsulin sensitivityen_US
dc.subjectweight lossen_US
dc.titleUse of metformin in obese adolescents with hyperinsulinemia: A 6-month, randomized, double-blind, placebo-controlled clinical trialen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu